B · Normal
[Aidi Pharmaceutical: ADC118 Tablets Received Drug Clinical Trial Approval Notice] On October 15th, Aidi Pharmaceutical (688488.SH) announced that the company and its wholly-owned subsidiaries received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, agreeing to conduct Phase III clinical trials of ADC118 tablets, a new class 1 drug under development in the field of anti-AIDS. The drug is a triple compound preparation composed of the independently developed HIV integrase strand transfer inhibitor ACC017, emtricitabine, and tenofovir alafenamide, and is intended to be used to treat adults infected with HIV-1.
A-share announcement express 🕐 2026-10-15 18:34
#clinical trial #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Yuanjie Technology: The first batch of equipment for the second phase of the op 10-15 19:51 [Northern Huachuang: Plans to acquire 100% equity of Novotech for 405 million yu 10-15 19:50 [Pengding Holdings: Chairman proposes to repurchase shares worth 300 million to 10-15 19:41 [Huafeng Chemical: Net profit is expected to increase by 98%-119% year-on-year i 10-15 19:39 [Changchuan Technology: The actual controller proposes to repurchase the company 10-15 19:24 [Evidion Lithium Energy: Net profit is expected to increase by 80%-90% year-on-y 10-15 19:07

Comments

0/500
Captcha (click to refresh)
No comments yet